All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Combinations Targeting PI3K/AKT/mTOR and MAPK/ERK Pathways Are Under Study in Endometrial Cancer

May 21st 2025

Combinations targeting PI3K/AKT/mTOR and MAPK/ERK pathways are under investigation to improve outcomes in patients with endometrial cancer.

TNBC Treatment Innovations Build on ADC Optimization, Provide Impetus for Individualized Care

May 21st 2025

Alexis LeVee, MD, discusses ongoing phase 3 trials evaluating the first-line use of ADCs in both PD-L1–positive and –negative TNBC.

Gastrointestinal Cancer Experts Spotlight the Most Exciting Abstracts Ahead of the 2025 ASCO Annual Meeting

May 21st 2025

Ahead of the 2025 ASCO Annual Meeting, experts in gastrointestinal cancers provide their top anticipated studies they will be watching for at the meeting.

FDA’s ODAC Votes in Favor of Risk/Benefit Profile of Subcutaneous Daratumumab for High-Risk Smoldering Myeloma

May 20th 2025

The FDA’s ODAC voted in favor of the risk/benefit profile of subcutaneous daratumumab in high-risk smoldering multiple myeloma.

The ‘Bar Is High’ to Usurp BCG, but Novel Therapies Could Drive Change in Bladder Cancer Management

May 20th 2025

Bogdana Schmidt, MD, MPH, discussed FDA-approved BCG-refractory treatments and recent shifts in BCG-naive NMIBC management.

Multidisciplinary Collaboration and Immunotherapy Help Overcome Treatment Challenges in MCC

May 20th 2025

Michael K. Wong, MD, PhD, FRCPC, discusses the landscape of Merkel cell carcinoma, including the role of immunotherapy and multidisciplinary treatment.

USC, UCLA Team Up for the World’s First-in-Human Bladder Transplant

May 20th 2025

Historic surgery, the result of years of research at Keck Medicine of USC and UCLA Health, opens the door for improved treatment of non-functioning bladders

Lymphodepletion Enhances MAR T-Cell Expansion and Persistence in R/R Lymphoma

May 20th 2025

Lymphodepletion was associated with enhanced MAR T-cell response and antitumor activity with MT-601 in patients with relapsed/refractory lymphoma.

FDA ODAC Votes Against the Applicability of STARGLO Data for Glofitamab Plus Chemo for U.S. Patients With R/R DLBCL

May 20th 2025

The FDA’s ODAC voted against the applicability of STARGLO trial results to U.S. patients with relapsed/refractory DLBCL.

Acoustic Cluster Therapy Platform Boosts Tumor Shrinkage in Metastatic CRC

May 20th 2025

The ACTIVATE trial confirmed the safety and enhanced efficacy of Acoustic Cluster Therapy plus chemotherapy in patients with metastatic colorectal cancer.

ctDNA Aids in Elucidating the Role of Select Therapies for CRC

May 20th 2025

In the colorectal cancer space, the role of ctDNA can help reduce the use of certain therapies.

Cetuximab β Plus FOLFIRI Displays Significant Clinical Activity in First-Line mCRC

May 20th 2025

Cetuximab β was effective and safe in patients with RAS/BRAF wild-type metastatic colorectal cancer.

Experts Preview Key Presentations to Watch in Gynecologic Oncology at ASCO 2025

May 20th 2025

Experts highlight key abstracts and presentations to keep an eye on in gynecologic oncology at the 2025 ASCO Annual Meeting.

FDA Awards RMAT Designation to BCB-276 CAR T-Cell Therapy for Diffuse Intrinsic Pontine Glioma

May 19th 2025

The B7-H3–directed CAR T-cell therapy BCB-276 received RMAT designation for the treatment of patients with diffuse intrinsic pontine glioma.

postMONARCH ctDNA Analysis Underscores Benefit of Abemaciclib Plus Fulvestrant in HR+ Advanced Breast Cancer

May 19th 2025

An exploratory ctDNA analysis from postMONARCH highlighted the benefit of abemaciclib plus fulvestrant across HR-positive breast cancer subgroups.

FDA Approval of Perioperative Durvalumab Plus Chemo Supports the Efficacy of a Novel MIBC Management Approach

May 19th 2025

Matthew Galsky, MD, discusses the significance of the FDA approval of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in MIBC.

Duration of Overweight/Obesity During Treatment Linked to Worse Outcomes in Pediatric Leukemia Patients

May 19th 2025

Collaborative Roswell Park/Columbia research uncovers greater risk of relapse and complications, lower survival rates.

FDA Grants Fast Track Designation to DLL3-Targeted ADC ZL-1310 in ES-SCLC

May 19th 2025

The DLL3-targeted antibody-drug conjugate ZL-1310 has received FDA fast track designation for patients with extensive-stage small cell lung cancer.

Belantamab Mafodotin–Based Combos Win Japanese Approval for R/R Myeloma

May 19th 2025

Two belantamab mafodotin–based combinations have been approved in Japan for relapsed/refractory multiple myeloma.

Combination Regimens Offer Options in Frontline RCC as Novel Agents Advance Through Pipeline

May 19th 2025

During an OncLive Peer Exchange filmed during ASCO GU, expert investigators discussed significant updates in the RCC space.